Bridging the Gap to Reach Treatment Goals in DLBCL
Tracking # 20-1040234
Free
There are no ratings for this course
Learn moreCourse overview
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, which typically occurs in patients over the age of 60 years. While chemoimmunotherapy (R-CHOP) has been considered the first line treatment option, approximately 40% of patient with DLBCL will fail to respond and experience a relapse. Autologous hematopoietic stem cell transplantation (AHCT) has been used as treatment for patients who experience a relapse; however, many patients are ineligible for the procedure due to age, comorbidities, or resistance to second-line chemoimmunotherapy. Novel treatment options have thus been introduced to the treatment landscape of DLBCL, including chimeric antigen receptor T-cell therapy (CAR T) with trial results displaying sustained remissions for relapsed patients. Because the options for treatment of DLBCL have changed rapidly, it is important for treating physicians to be aware of the options that are available as well as assist them in overcoming barriers that may impact their treatment. Join us for this educational Med Table Talk LIVE on Bridging the Gap to Reach Treatment Goals in DLBCL as our experts have a candid conversation about the available treatment options for DLBCL, how cellular therapists and community physicians must communicate to ensure adequate care between referring and treating physicians, and how to recognize and address common treatment barriers.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Medicine
Area of Critical Need Medical Doctor
Medical Doctor
Florida Board of Nursing
Advanced Practice Registered Nurse
Registered Nurse
Florida Board of Pharmacy
Pharmacist
Disclosure statements
Faculty Disclosures
Planner/Presenter
Christopher R. Flowers, MD, MS, FASCO
Division Head, ad Interim, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
John M O’Quinn Endowed Chair in Cancer Research
MD Anderson Cancer Center
Houston, TX
Christopher R. Flowers, MD, MS, FASCO has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, AstraZeneca, Bayer, BeiGene, Bio Ascend, Bristol Myers Squibb, Celgene, Denovo Biopharma, Foresight Diagnostics, Genentech/Roche, Genmab, Gilead, Karyopharm, N Power, Pharmacyclics/Janssen, Seagen, Spectrum
Speakers’ Bureau: AbbVie, AstraZeneca, Bayer, BeiGene, Bio Ascend, Bristol Myers Squibb, Celgene, Denovo Biopharma, Foresight Diagnostics, Genentech/Roche, Genmab, Gilead, Karyopharm, Pharmacyclics/Janssen, Seagen, Spectrum
Research Grant: 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD Serono, Genentech/Roche, Gilead, Guardant, Iovance, Janssen Pharmaceutical, Kite, Morphosys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi
Stock Ownership: Foresight Diagnostics, N Power
Planner/Presenter
Sergio A. Giralt, MD, FACP
Melvin Berlin Family Chair in Myeloma Research
Professor of Medicine, Weill Cornell Medical College
Deputy Head, Division of Hematologic Malignancies
Attending Physician, Adult BMT Service
Memorial Sloan Kettering Cancer Center
New York, NY
Sergio A. Giralt, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Actinium Pharmaceuticals, Inc., Amgen Inc., Bristol Myers Squibb, Celgene Corp., Janssen Pharmaceuticals, Omeros Corporation, Pfizer Inc., Sanofi, Takeda Pharmaceutical Co.
Research Grant: Actinium Pharmaceuticals, Inc, Amgen Inc., Bristol Myers Squibb, Celgene Corp., GlaxoSmithKline, Jazz Pharmaceuticals, Inc., Janssen Pharmaceuticals, Omeros Corporation, Pfizer Inc., Sanofi
Planner/Presenter
Sanjay K. Juneja, MD
Hematologist & Medical Oncologist
Chief of Oncology
Baton Rouge General Hospital
Mary Bird Perkins Cancer Center
Baton Rouge, LA
Sanjay K. Juneja, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Daiichi San Guardant 360
Speakers’ Bureau: AstraZeneca Pharmaceuticals, Daiichi Sankyo, Guardant 360, Merck & Co., Inc., Tempus
Stock Ownership: Phenomune, xCures
Independent Contractor: xCures
Planner/Presenter
Sanjay Sharma, MD
St. Jude Crosson Cancer Institute
Providence OC Cancer Institute
Fullerton, CA
Sanjay Sharma, MD has a financial interest/relationship or affiliation in the form of:
Speakers’ Bureau: Amgen, AstraZeneca, Bristol Myers Squibb, Guardant, Merck, Regeneron
Presenter
Rayne H. Rouce, MD, BS
Associate Professor
Department of Pediatrics
Texas Children’s Cancer Center for Cell and Gene Therapy
Baylor College of Medicine
Houston, TX
Rayne H. Rouce, MD, BS, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Novartis Pharmaceuticals Corporation, Pfizer Inc.
Research Grant: Tessa Therapeutics
All of the relevant financial relationships of individuals for this activity have been mitigated.